What is Acroname?
Based in Boulder, Acroname specializes in the design, development, and distribution of sophisticated products for automated manufacturing, embedded robotics, and complex control systems. At the core of its value proposition is the proprietary BrainStem technology, a modular and scalable framework that serves as the backbone for high-volume consumer product testing and industrial automation. The company's portfolio, which includes Manufacturing Test Modules and Programmable USB Hubs, addresses critical needs for both business-to-business and consumer-facing applications. By providing reliable, high-performance hardware and software tools, Acroname has solidified its position as a foundational partner for manufacturers seeking to optimize their production lines and testing protocols.
How much funding has Acroname raised?
Acroname has raised a total of $441K across 2 funding rounds:
Debt
$150K
Debt
$291K
Debt (2020): $150K with participation from PPP
Debt (2021): $291K led by PPP
Key Investors in Acroname
PPP
Public-Private Partnership
What's next for Acroname?
With the successful closure of this late-stage financing round, Acroname is well-positioned to accelerate its product development roadmap and expand its footprint in the automated manufacturing landscape. The strategic allocation of these funds will likely focus on enhancing the scalability of the BrainStem ecosystem, ensuring that the company remains at the forefront of the transition toward smarter, more autonomous factory environments. As the demand for precision testing equipment continues to rise, Acroname's ability to integrate its modular solutions into diverse OEM applications will be a primary driver of its future growth. The company is expected to leverage this capital to deepen its market penetration, potentially exploring new verticals within the robotics sector while maintaining its commitment to high-quality, reliable engineering solutions.
See full Acroname company page
